This is another slow day (in terms of news) and this time I promise to keep it short and actually keep it short as the sector is so volatile right now that it is almost impossible to explain why some stocks are going higher and others lower. For instance, I have no idea why ECYT […]
April 15 Biotech Update
Another day and nothing to talk about except more selling. There is really nothing more to say at this point that has not already been said. There is a significant correction in the growth sector of the market and funds are hitting the sell button every day and it will continue despite the fundamentals of […]
April 14 Biotech Update-
It was a really slow day on the news front, which could simply relate to the start of a pre-holiday week. I did not think it would extend all the way to today but so far nothing major happening in the sector. I will touch on a couple of ideas but will keep this short […]
April 11 Biotech Update- The Beating Continues
Well, there is not much to say about the market and sector other than selling is in vogue and there does not seem to be a clear catalyst that could change the tone of the market. I would also remind you that the apparent catalyst of this negative turn (pricing letter from Congress to GILD) […]
Celgene Markman Hearing Documents
Celgene Reply Markman Decl ISO Celgene Markman Reply-1 CELG brief Natco got RLI illegally blocks access to employee who got RLI fro Natco
April 9 Biotech Update
As we have been apt to do, this morning was relatively strong but we need to see how this holds up throughout the day. If we are to be optimistic, then having a rally so close to the negative pricing headlines is good as was the decent performance of a number of small caps yesterday. […]
April 8 Biotech Update- Revenge of the Pricing Questions
While I was expecting to talk a little about AGIO today, I want to go back to the macro sector sentiment as the proverbial hits keep on coming with ESRX making more noise about Sovaldi prices. In general, ESRX is arguing that GILD is going to bankrupt the entire healthcare system and that they will […]
April 7 Biotech Update- An Active AACR
So a lot to talk about and I will briefly touch on a lot and then expand later this week as I doubt many days will be a busy as today in term of news. The sector had a good morning but we have seen this before and at this point it will not be […]
April 4 Biotech Update
As often happens when you have small children the best laid plans are often disrupted. So I am taking care of a child with a suspected strep throat infection (the irony is certainly not lost on me given how much time I spend researching antibiotics and the companies that are developing new treatments) and this […]
April 2nd Biotech Update
The sector was a little manic today in that the large caps continue to find a good bid but as you move down the market cap food chain the price action is more mixed. This makes perfect sense as investors are slowly coming back into the sector and are going after value and the security […]
April 1 Biotech Update- Trying Not to be Fooled by the Rally
So it appears that window dressing is over and people are now willing to buy small cap biotechs but as with every other morning we need to see if this interest continues throughout the day. I am not completely convinced that the small cap selling was entirely window dressing but there is something to be […]
March 31 Biotech Update- Is this the Bounce We are Looking For?
So this seems to be the rally we were looking for but that is assuming it does not fade in the afternoon like every other recent rally attempt. So far the rally is a little more broad based and stronger but we have seen this story before. That being said even if this is the […]
A Follow Up
Just a really quick update. I had a good email exchange with one of the lead ACLF trial investigators and he basically confirmed what CNAT noted in their CC. The exclusion/inclusion criteria were so restrictive that it was virtually impossible for anyone to qualify. The investigator was confident that the issues were corrected with the […]
March 28 Biotech Update- Treading Water Can Be Dangerous
So today was another mixed day for biotechs but the large caps still are above the recent lows and even the “bad” news of the sovaldi new scripts being down for a week was not enough to push GILD to new lows or even really have much pin action across the sector. So all of […]
March 26- Biotechs are Not Dead Yet
This is a better day but sellers still seem there but buying seems more concerted today. It appears that yesterday was the buyers dipping their toes in the water to make sure the coast was clear and today they seemed much more willing to put cash to work. As we saw with yesterday, however, the […]
March 25 Biotech Update- Would it Help to Cry Uncle?
Today certainly started as a better day in the sector but I would be careful of chasing this move. Ideally, we spend time building a base but a day or two of running is possible given the oversold conditions in the space. At this point I would lean towards the sector having put in a […]
March 24 Biotech Update- Being Kicked When You Are Down
Every sell off starts the bubble talk and the more severe the selling the more intense the bubble talk. What is interesting about this time is that the bubble talk has a broader audience as the sector seems to have been on more radars. As I have been saying for awhile, this sell off is […]
March 21 Biotech Update
[This was written Friday but the site was down and I was unable to post it. I am publishing it as it was Friday and will write another column later today for more recent news] Well, it was a manic day with a very nice win followed by the broader morning bloodbath in the sector. […]
March 19 Biotech Update- Staying Focused
The trading today seemed a little calm (could be because I was out most of the morning) but this is not bad given the recent swings. A period of steady base building might be the most productive outcome but we still need to see many more days before we can be confident as to what […]
Quick Confirmation
I just talked to CNAT and confirmed that they have not seen any lipid abnormalities either at the pre-clinical or clinical stages. In addition, they noted that there is no reason to expect the emricisan mechanism of action to generate any lipid abnormalities. Obviously, this does not completely rule anything out but simply confirms my […]
